RecruitingNCT07401615

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions: an Italian Multicenter Retrospective Analysis (STRILL IT)


Sponsor

Istituto Clinico Humanitas

Enrollment

150 participants

Start Date

Nov 25, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites. Even so, some patients later develop a local recurrence, meaning the cancer comes back in the same area that was previously treated with radiation. When this happens, treatment options are limited. Surgery can sometimes remove the recurrent tumor, but many patients are not able to have surgery because of their general health or because the tumor is difficult to remove. For these patients, a second course of radiotherapy (called re-irradiation) may be the only possible treatment. One type of radiotherapy, called stereotactic body radiotherapy (SBRT), delivers very high doses of radiation very precisely. SBRT has been used successfully as a second treatment after standard radiotherapy in some patients. However, there is very little information about using SBRT again in patients who already received SBRT the first time. Because only small studies have been done and the patients were very different from each other, doctors still do not know enough about how safe and effective a second SBRT treatment is. In particular, it is still unclear whether giving another high-dose radiation treatment is possible without causing serious side effects. More research is needed to better understand this option and help guide treatment decisions for patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a precise form of radiation treatment (called SBRT, or stereotactic body radiotherapy) can be safely and effectively given a second time to people with lung cancer or lung metastases who previously received SBRT. **You may be eligible if...** - You have inoperable lung cancer or lung metastases that were previously treated with high-dose SBRT - Your cancer has come back in the same area (called a local recurrence) - Your previous SBRT was given more than 12 months ago at a high enough dose - Your overall health is reasonably good (performance status 0–2) - You do not have active cancer spread to other parts of the body (or it is well controlled) **You may NOT be eligible if...** - You previously had conventional (non-SBRT) radiation to the area - The re-irradiation is being done for palliative (comfort) purposes only Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(11)

AST Papa Giovanni XXIII

Bergamo, Bergamo, Italy

Radiotherapy Department, Ospedale Bellaria Carlo Alberto Pizzardi

Bologna, Bologna, Italy

REM Radioterapia

Catania, Catania, Italy

Radiation oncology unit, Ospedale San Raffaele

Milan, Milano, Italy

Radiotherapy Department, Istituto Europeo di Oncologia

Milan, Milano, Italy

IRCCS Humanitas Research Hospital

Rozzano, Milano, Italy

Radiotherapy Department, IRCCS Istituto Nazionale Fondazione G. Pascale

Naples, Napoli, Italy

Centro Fondazione Policlinico Universitario "A. Gemelli", Radioterapia Oncologica

Roma, Roma, Italy

Radioterapia Oncologica - Ospedale dell'Angelo

Venezia, Venezia, Italy

Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center

Negrar, Verona, Italy

AOUI Verona, DAI Chirurgia e Oncologia - Radioterapia Oncologica

Verona, Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07401615


Related Trials